Loading...
OTCM
HOFBF
Market cap61mUSD
Apr 14, Last price  
0.16USD
Name

Hofseth Biocare ASA

Chart & Performance

D1W1MN
P/E
—
P/S
2.43
EPS
—
Div Yield, %
—
Shrs. gr., 5y
6.05%
Rev. gr., 5y
30.59%
Revenues
257m
+32.09%
171,0001,183,00026,015,00062,936,00019,769,00055,137,00020,204,000118,476,00060,740,00067,778,00069,252,00087,616,000120,448,000194,874,000257,417,000
Net income
-123m
L+15.67%
-9,387,000-19,036,000-73,860,000-52,136,000-66,918,000-100,194,000-147,450,000-16,475,000-84,768,000-89,209,000-102,090,000-126,463,000-137,389,000-106,683,000-123,405,000
CFO
-10m
L
-12,445,000-19,470,000-48,006,000-83,652,000-62,257,0007,967,000-67,226,000-25,485,000-28,625,000-31,060,000-61,632,000-61,779,000-45,168,0002,761,000-9,818,000

Profile

Hofseth BioCare ASA engages in providing value added biomarine ingredients for human and animal applications in Norway and internationally. Its products include Brilliant salmon oil; OmeGo salmon oil for the maintenance of healthy cholesterol and cardiovascular function; ProGo, a salmon protein hydrolysate powder used as a fast absorbing protein supplement; CalGo, a marine calcium powder produced to support cartilage function and joint health; CollaGo, a collagen peptide powder to enhance the beauty of hair, skin, and nails; and PetGo, a non-soluble protein. The company distributes its products through distributors, agents, and its own sales force. It has a research agreement with Stanford University School of Medicine for pre-clinical and clinical research on necrotizing enterocolitis and irritable bowel syndrome. The company was founded in 2000 and is headquartered in Ålesund, Norway.
URL
https://hofsethbiocare.com
IPO date
Dec 02, 2011
Employees
56
Domiciled in
NO
Incorporated in
NO

Valuation

Title
NOK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
257,417
32.09%
194,874
61.79%
120,448
37.47%
Cost of revenue
169,553
197,179
138,482
Unusual Expense (Income)
NOPBT
87,864
(2,305)
(18,034)
NOPBT Margin
34.13%
Operating Taxes
1,181
Tax Rate
NOPAT
87,864
(2,305)
(19,215)
Net income
(123,405)
15.67%
(106,683)
-22.35%
(137,389)
8.64%
Dividends
Dividend yield
Proceeds from repurchase of equity
(215)
70,777
BB yield
Debt
Debt current
183,687
13,395
Long-term debt
204,727
193,587
Deferred revenue
Other long-term liabilities
111,643
Net debt
(25,577)
326,833
170,243
Cash flow
Cash from operating activities
(9,818)
2,761
(45,168)
CAPEX
(4,073)
(8,194)
(17,778)
Cash from investing activities
(4,074)
(14,992)
(17,778)
Cash from financing activities
15,578
3,694
45,452
FCF
210,869
(38,133)
(2,182)
Balance
Cash
25,577
23,890
29,881
Long term investments
37,691
6,858
Excess cash
12,706
51,837
30,717
Stockholders' equity
3,422
3,264
148,998
Invested Capital
169,525
318,665
221,480
ROIC
36.00%
ROCE
50.80%
EV
Common stock shares outstanding
412,167
395,081
374,737
Price
Market cap
EV
EBITDA
127,645
34,108
12,378
EV/EBITDA
Interest
15,685
7,543
9,954
Interest/NOPBT
17.85%